

Estimated Direct Spending and Revenue Effects of H.R. 6, Substance Use–Disorder Prevention that Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and Communities Act

OPIOID-CONF\HR6-CONF-COMBO_04.XML, September 25, 2018 (9:50 p.m.)

September 27, 2018

Millions of dollars, by fiscal year. **2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2019- 2019- 2023 2028**

INCREASES OR DECREASES (-) IN DIRECT SPENDING OUTLAYS

TITLE I—MEDICAID PROVISIONS TO ADDRESS THE OPIOID CRISIS

1001.	At-risk youth Medicaid protection	*	5	5	5	10	10	10	10	10	10	25	75
1002.	Health insurance for former foster youth	0	0	0	0	*	10	21	33	46	61	*	171
1003.	Demonstration project to increase substance use provider capacity under the Medicaid program	13	35	58	67	63	9	2	3	3	3	236	256
1004.	Medicaid drug review and utilization	*	*	1	1	1	1	1	1	1	1	2	5
1006.	Medicaid health homes for substance-use-disorder Medicaid enrollees	94	58	62	56	52	48	43	38	32	25	323	509
1012.	Help for moms and babies	1	2	4	5	5	6	6	6	6	7	17	48

TITLE II—MEDICARE PROVISIONS TO ADDRESS THE OPIOID CRISIS^a

2001.	Expanding the use of telehealth services for the treatment of opioid use disorder and other substance use disorders	0	1	1	1	2	2	2	3	3	4	4	18
2002.	Comprehensive screenings for seniors	0	1	1	1	1	1	2	2	2	2	4	13
2003.	Every prescription conveyed securely	0	0	-24	-35	-33	-30	-33	-32	-31	-32	-92	-250
2004.	Requiring prescription drug plan sponsors under Medicare to establish drug management programs for at-risk beneficiaries	0	0	0	-7	-7	-7	-8	-8	-9	-10	-13	-55
2005.	Medicare coverage of certain services furnished by opioid treatment programs	0	0	15	20	25	30	35	40	40	45	60	250
2006.	Encouraging appropriate prescribing under Medicare for victims of opioid overdose	0	0	*	*	*	*	*	*	*	*	*	*
2008.	Suspension of payments by Medicare prescription drug plans and MA–PD plans pending investigations of credible allegations of fraud by pharmacies	0	-1	-1	-1	-1	-1	-1	-1	-1	-1	-4	-9

TITLE III—FDA AND CONTROLLED SUBSTANCE PROVISIONS

3201.	Allowing for more flexibility with respect to medication-assisted treatment for opioid use disorders (b)	1	4	7	48	57	55	56	56	56	54	117	395
-------	--	---	---	---	----	----	----	----	----	----	----	-----	-----

TITLE IV—OFFSETS

4001.	Promoting value in Medicaid managed care	0	0	-144	-434	-305	-314	-339	-365	-390	-420	-882	-2,710
4002.	Requiring reporting by group health plans of prescription drug coverage information for purposes of identifying primary payer situations under the Medicare program	0	-5	-5	-5	-5	-5	-5	-5	-5	-5	-20	-45

TITLE V—OTHER MEDICAID PROVISIONS

5042.	Medicaid providers are required to note experiences in record systems to help in-need patients	*	*	*	*	*	*	*	*	*	*	*	*
5052.	State option to provide Medicaid coverage for certain individuals with substance use disorders who are patients in certain institutions for mental diseases	0	40	195	366	447	0	0	0	0	0	1,048	1,048

Estimated Direct Spending and Revenue Effects of H.R. 6, Substance Use–Disorder Prevention that Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and Communities Act

OPIOID-CONF\HR6-CONF-COMBO_04.XML, September 25, 2018 (9:50 p.m.)

September 27, 2018

Millions of dollars, by fiscal year.	2019	2020	2021	2022	2023	2024	2025	2026	2027	2028	2019- 2023	2019- 2028
TITLE VI—OTHER MEDICARE PROVISIONS^a												
6042. Opioid use disorder treatment demonstration program	0	0	15	26	24	23	15	4	*	*	66	107
6052. Grants to provide technical assistance to outlier prescribers of opioids (c)	8	19	38	8	4	0	0	0	0	0	75	75
6062. Electronic prior authorization for covered Part D drugs	0	0	*	*	*	*	*	*	*	*	*	*
6064. Expanding eligibility for medication therapy management programs under Part D	0	0	*	*	*	*	*	*	*	*	*	*
6083. Expanding access under the Medicare program to addiction treatment in Federally qualified health centers and rural health clinics (c)	2	4	2	0	0	0	0	0	0	0	8	8
TITLE VII—PUBLIC HEALTH PROVISIONS	0	0	0	0	0	0	0	0	0	0	0	0
TITLE VIII—MISCELLANEOUS												
8003. Mandatory advance electronic information for postal shipments Off-budget outlays	2	3	3	3	3	3	3	3	3	3	14	29
8082. Improving recovery and reunifying families (c)	1	3	3	3	2	2	1	0	0	0	12	15
Total, Changes in On-Budget Direct Spending Outlays	120	166	232	126	343	-161	-193	-216	-237	-256	988	-75
Total, Changes in Direct Spending (Unified-Budget)	122	169	235	129	346	-158	-190	-213	-234	-253	1,002	-46

INCREASES OR DECREASES (-) IN REVENUES^d

3012. Notification, nondistribution, and recall of controlled substances	*	*	*	*	*	*	*	*	*	*	*	*
3013. Single source pattern of imported illegal drugs	*	*	*	*	*	*	*	*	*	*	*	*
3022. Restricting entrance of illicit drugs	*	*	*	*	*	*	*	*	*	*	*	*
3201. Allowing for more flexibility with respect to medication-assisted treatment for opioid use disorders (b)												
On-budget	*	*	-1	-6	-9	-9	-9	-10	-11	-11	-16	-66
Off-budget	*	*	*	-2	-3	-3	-4	-4	-4	-4	-6	-25
3273. Amendments	*	*	*	*	*	*	*	*	*	*	*	*
8023. Unfair or deceptive acts or practices with respect to substance use disorder treatment service and products	*	*	*	*	*	*	*	*	*	*	*	*
8122. Criminal penalties	*	*	*	*	*	*	*	*	*	*	*	*
Total, Changes in On-Budget Revenues	*	*	-1	-6	-9	-9	-9	-10	-11	-11	-16	-66
Total, Changes in Revenues (Unified-Budget)	*	-1	-1	-8	-12	-12	-13	-14	-14	-15	-22	-90

Estimated Direct Spending and Revenue Effects of H.R. 6, Substance Use–Disorder Prevention that Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and Communities Act

OPIOID-CONF\HR6-CONF-COMBO_04.XML, September 25, 2018 (9:50 p.m.)

September 27, 2018

Millions of dollars, by fiscal year. **2019 2020 2021 2022 2023 2024 2025 2026 2027 2028** **2019- 2019- 2023 2028**

NET INCREASE OR DECREASE (-) IN DEFICITS FROM REVENUE AND DIRECT SPENDING

Changes in On-Budget Deficits	121	166	233	132	351	-152	-184	-206	-226	-245	1,004	-10
Total, Changes in Deficits (Unified-Budget)	123	170	237	138	358	-145	-177	-199	-220	-239	1,024	44

Memorandum:

Budget authority equals outlays for all of the direct spending sections except for the following three provisions:

6052. Grants to provide technical assistance to outlier prescribers of opioids												
Budget Authority	75	0	0	0	0	0	0	0	0	0	75	75
Estimated Outlays	8	19	38	8	4	0	0	0	0	0	75	75
6083. Expanding access under the Medicare program to addiction treatment in Federally qualified health centers and rural health clinics												
Budget Authority	8	0	0	0	0	0	0	0	0	0	8	8
Estimated Outlays	2	4	2	0	0	0	0	0	0	0	8	8
8082. Improving recovery and reunifying families												
Budget Authority	15	0	0	0	0	0	0	0	0	0	15	15
Estimated Outlays	1	3	3	3	2	2	1	0	0	0	12	15
All other sections												
Budget Authority	112	143	193	119	340	-160	-191	-213	-234	-253	907	-144
Estimated Outlays	112	143	193	119	340	-160	-191	-213	-234	-253	907	-144
Total, Changes in Direct Spending (Unified-Budget)												
Budget Authority	210	143	193	119	340	-160	-191	-213	-234	-253	1,005	-46
Estimated Outlays	122	169	235	129	346	-158	-190	-213	-234	-253	1,002	-46

Source: Congressional Budget Office and the staff of the Joint Committee on Taxation.

Notes: Components may not sum to totals because of rounding. * = between -\$500,000 and \$500,000.

- Medicare provisions include interactions with Medicare Advantage payments, the effect on Medicare Part A and B premiums, and TRICARE.
- Proposal would affect both direct spending and revenues, which are shown separately.
- Budget authority does not equal outlays; see memorandum.
- For revenues, negative numbers indicate an increase in the deficit.

FDA = Food and Drug Administration; MA-PD = Medicare Advantage plan that offers prescription drug coverage; TRICARE = the health plan operated by the Department of Defense.